Journal of Biological Chemistry · 2000 · 115 citations · 34 references
MedicineCell BiologyMolecular BiologyMolecular OncologyOncogenesTranscriptional RegulationCancer Cell SignalingOncogene ActivationOncogenic Signaling PathwaysOncogenic VirusesTumor Suppressor Gene InactivationTumor Suppressor GenesAdenoviral OncogenesisBeta-catenin RegulationCancer Signaling PathwaysCyclin RegulationOncogenic TransformationTumor Suppressor LossTumor Suppressor P53Tumor Suppressor Pathways
CBP and its homologue p300 play significant roles in cell differentiation, cell cycle, and anti-oncogenesis. We demonstrated that beta-catenin, recently known as a potent oncogene, and CBP/p300 are associated through its CH3 region, which is a primary target of adenoviral oncoprotein E1A and various nuclear proteins, such as p53, cyclin E, and AP-1, and both are colocalized in the nuclear bodies. CBP/p300 potentiated Lef-mediated transactivation of beta-catenin, and E1A, a potent inhibitor of CBP/p300, repressed its transactivation. Furthermore, overexpression of stable beta-catenin mutant competitively suppressed the p53-dependent pathway. These may be a key mechanism of beta-catenin involved in oncogenic events underlying disruption of tumor suppressor function through CBP/p300.
34
Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC
Patrice J. Morin, Andrew B. Sparks, Vladimír Kořínek et al. · Science · 1997 · 3.9K citations
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Osamu Tetsu, Frank McCormick · Nature · 1999 · 3.6K citations
Medicine, Cell Biology, Oncology +14
Yasutomi Kamei, Lan Xu, Thorsten Heinzel et al. · Cell · 1996 · 2.2K citations · Full text
Phosphorylated CREB binds specifically to the nuclear protein CBP
John C. Chrivia, Roland P.S. Kwok, Ned Lamb et al. · Nature · 1993 · 2.1K citations